ME (23andMe Holding Co) 6-1 Month Momentum % : -44.27% (As of Dec. 11, 2024)

View and export this data going back to 2021. Start your Free Trial

What is 23andMe Holding Co 6-1 Month Momentum %?

6-1 Month Momentum % is the total return of the stock from 6-month ago to 1-month ago. As of today (2024-12-11), 23andMe Holding Co's 6-1 Month Momentum % is -44.27%.

The industry rank for 23andMe Holding Co's 6-1 Month Momentum % or its related term are showing as below:

ME's 6-1 Month Momentum % is ranked worse than
91.3% of 230 companies
in the Medical Diagnostics & Research industry
Industry Median: -1.425 vs ME: -44.27

Competitive Comparison of 23andMe Holding Co's 6-1 Month Momentum %

For the Diagnostics & Research subindustry, 23andMe Holding Co's 6-1 Month Momentum %, along with its competitors' market caps and 6-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

23andMe Holding Co's 6-1 Month Momentum % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, 23andMe Holding Co's 6-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where 23andMe Holding Co's 6-1 Month Momentum % falls into.

23andMe Holding Co (NAS:ME) 6-1 Month Momentum % Calculation

6-1 Month Momentum % is calculated as following:

6-1 Month Momentum %

( Price 1-month ago

Price 6-month ago

- 1 )

100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

23andMe Holding Co (NAS:ME) 6-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 6-1 Month Momentum % measures the total return to a stock over the past six months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.

23andMe Holding Co 6-1 Month Momentum % Related Terms

Thank you for viewing the detailed overview of 23andMe Holding Co's 6-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.

23andMe Holding Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » 23andMe Holding Co (NAS:ME) » Definitions » 6-1 Month Momentum %

Comparable Companies

Traded in Other Exchanges

N/A

Address

349 Oyster Point Boulevard, South San Francisco, CA, USA, 94080

Website

https://www.23andme.com

23andMe Holding Co is a consumer-facing healthcare technology company, primarily involved in the sale of direct-to-consumer personal genome services, or PGS, through DNA collection kits shipped via mail. The company provides users access to reports summarizing estimated genetic ancestry breakdown, phenotypic trait reports, and various health predisposition and disease carrier reports. Its segment includes Consumer and Research Services and Therapeutics. The company generates maximum revenue from the Consumer and Research Services segment.

Executives

Kathy L Hibbs	officer: See Remarks	C/O VIROLOGIC, 345 OYSTER POINT BLVD, SOUTH SAN FRANCISCO CA 94080
William G Richards	officer: Head of Therapeutics Discovery	160 KELLY AVE, HALF MOON BAY CA 94019
Richard H Scheller	director	C/O GENENTECH INC, 1 DNA WAY MS 49, SOUTH SAN FRANCISCO CA 94080-4990
Joseph Anthony Selsavage	officer: Interim CFO	490 HILL STREET, APT 5, SAN FRANCISCO CA 94114
Kenneth J. Hillan	officer: Head of Therapeutics	C/O ACHAOGEN, INC., 7000 SHORELINE COURT, SUITE 371, SOUTH SAN FRANCISCO CA 94080
Evan Lovell	director, officer: Chief Financial Officer	27 SOUTH PARK STREET, SUITE 200, SAN FRANCISCO CA 94107
Hernandez Sandra R Md	director	BLACKBAUD INC, 2000 DANIEL ISLAND DRIVE, CHARLESTON SC 29492
Paul D Johnson	officer: VP, General Manager-Consumer	440 N BARRANCA AVE #3550, COVINA CA 91723
Tracy Keim	officer: See Remarks	6107 ARROWROOT LANE, RANCHO PALOS VERDES CA 90275
Steven Lemon	officer: Vice President, Engineering	1020 CHERRY AVENUE, SAN JOSE CA 95125
Steven J Schoch	officer: See Remarks	2748 BUSH STREET, SAN FRANCISCO CA 94115
Frederick Mark Kohler	officer: Vice President, People	1004 UNION STREET, ALAMEDA CA 94501
Sequoia Capital Global Growth Ii Principals Fund, L.p.	10 percent owner	2800 SAND HILL ROAD, SUITE 101, MENLO PARK CA 94025
Abeec 2.0, Llc	10 percent owner	171 MAIN STREET, SUITE 259, LOS ALTOS CA 94022
Anne Wojcicki	director, 10 percent owner, officer: Chief Executive Officer	C/O AJAX I HOLDINGS, LLC, 667 MADISON AVENUE, NEW YORK NY 10606